DUSA Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 19   

Articles published

DUSA 0.0000
price chart
Caliber Imaging & Diagnostics Names New CFO
"During my tenure at DUSA Pharmaceuticals, I came to appreciate the specific challenges facing a small publicly traded company developing new technology for the skin cancer market,� Christopher said. �In my new role at Caliber I.D., I intend to work ...
India's Sun to Acquire Ranbaxy in $3.2 Billion Stock Deal (2)
This is the sixth deal Sun Pharma has announced in six years, according to data compiled by Bloomberg. The company controls Taro Pharmaceutical Industries Ltd.
Sun Pharma buys Ranbaxy to create generics giant  Livemint
Related articles »  
Dilip Shanghvi | The Dealmaker
Within two years, Sun Pharma bought two more drug makers in the US�Dusa Pharmaceuticals Inc. and the generic business of URL Pharma Inc. Apart from India and the US, Sun has manufacturing facilities in Israel, Mexico, Hungary, Canada, Bangladesh ...
Related articles »  
Ranbaxy buy in line with Sun's strategy
Since 1996, the company has done 16 major deals, including the buyouts of Caraco, Taro, DUSA Pharma and URL's generic business.
DNA of Ranbaxy Laboratories lives on... We have a perfect fit: Sun Pharma chief
Israel Makov's tenure as chairman of Sun Pharmaceuticals Industries has seen three acquisitions - URL Pharma, Dusa Pharmaceutical and now Ranbaxy Laboratories - and a joint venture to develop therapies for ocular diseases with US-based Intrexon. A ...
Related articles »  
Tekmira and Theralase Leaders in Innovative Drug Therapies
The Burnaby, BC-based company has reached commercialization by licensing Marqibo, an FDA-approved liposomal formulation of vincristine for the treatment of certain acute lymphoblastic leukemia (ALL) patients, to Talon Therapeutics, which was ...
Related articles »  
Reed Smith LLP | Leveraging Firm-Wide Resources in N.J. and Beyond
Representative clients of the department are Wells Fargo NA, GlaxoSmithKline, United Airlines, Royal Bank of Scotland, Merck & Co.
WeissLaw LLP Investigates Dusa Pharmaceuticals Inc